Analysts: Auxilium Resets Xiaflex Goal Date and 3 Other Research Notes to Review

Auxilium (NASDAQ:AUXL): After the FDA told Auxilium that it was postponing the PDUFA (Prescription Drug User Free Act) goal date for the company’s Xiaflex drug for Peyronie’s Disease, Leerink notes that the agency did not ask for any additional clinical studies prior to the revised PDUFA date. Because of this, the firm thinks that there is an 80 percent chance that the clinical data that has already been obtained will support approval of the drug. The firm reiterates a $21 price target and an Outperform rating on Auxilium.


Harsco (NYSE:HSC): After conducting a sum of the parts analysis of Harsco, KeyBanc thinks that the stock may jump 20 percent-55 percent from current levels. The firm predicts that the company may look to sell its infrastructure business and it keeps a Buy rating on the stock.


Joy Global (NASDAQ:JOY): RW Baird lowered its price target on Joy Global following partial third quarter results. The firm cited lowered bookings guidance but remains positive citing its share buyback program, expanded cost reductions, and current valuation. The shares are still rated Outperform with their price target dropped from $69 to $57.


Gordmans Stores (NASDAQ:GMAN): RW Baird notes that Gordmans Stores reported better than expected second quarter results and paid a special dividend, despite lowered second quarter guidance. The firm remains positive, citing easing comps, strong unit growth, and management’s conservative outlook. The shares are rated Outperform with a $15 price target.


Don’t Miss: Will Google’s Romantic Soap Opera Be Bad for Its Image?